Reducing Hypotensive Anesthesia Use With TXA During Orthognathic Surgery
Does Tranexamic Acid Reduce the Need for Deliberate Hypotensive Anesthesia Within Orthognathic Surgery? A Prospective Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Timothy Weber, MD
- Phone Number: (314) 750-5550
- Email: webertm@uab.edu
Study Contact Backup
- Name: Brian Kinard, DMD, MD
- Phone Number: (205) 934-5334
- Email: briankinard@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- UAB Hospital-Highlands
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Bimaxillary orthognathic surgery completed at UAB Highlands Hospital
Exclusion Criteria:
- History of hypertension or previously diagnosed cardiac problems
- Bleeding diathesis
- TXA medically contraindicated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Patients Receiving Tranexamic Acid with Avoidance of Hypotensive Anesthesia
|
The anesthesia team will be asked to avoid deliberate hypotensive anesthesia and maintain blood pressure closer to the patient's baseline throughout the surgery.
1g of tranexamic acid will be given intravenously to patient undergoing orthognathic surgery as routinely performed about 5-15 minutes before first surgical incision.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgeon's Analysis of Surgical Field Visualization
Time Frame: through surgical procedure, and average of 2 hours
|
The surgeon will evaluate surgical field visibility using Fromme's ordinal scale.
Fromme's ordinal scale (often referred to as the Fromme-Boezaart scale) is a 5-point, 0-5 visual grading system used by surgeons to assess the quality of the surgical field, primarily based on bleeding and suction frequency.
It measures surgical conditions from 0 (no bleeding, perfectly dry) to 5 (severe bleeding, flooding the field).
|
through surgical procedure, and average of 2 hours
|
|
Percentage of Hours to Maintain a Mean Arterial Pressure
Time Frame: through surgical procedure, and average of 2 hours
|
Tracking mean arterial pressures throughout surgery, evaluating if patient's blood pressure can be reliably kept around patient's baseline instead of deliberate hypotensive anesthesia.
|
through surgical procedure, and average of 2 hours
|
|
Average Volume of Blood Loss on a Scale
Time Frame: through surgical procedure, and average of 2 hours
|
Volume of blood loss recorded during surgical case based on the Fromme's scale.
Fromme's ordinal scale (often referred to as the Fromme-Boezaart scale) is a 5-point, 0-5 visual grading system used by surgeons to assess the quality of the surgical field, primarily based on bleeding and suction frequency.
It measures surgical conditions from 0 (no bleeding, perfectly dry) to 5 (severe bleeding, flooding the field), widely applied in orthognathic, sinus, and spine surgeries to evaluate the effectiveness of techniques like hypotensive anesthesia.
|
through surgical procedure, and average of 2 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brian Kinard, DMD, MD, University of Alabama at Birmingham
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Hemorrhage
- Intraoperative Complications
- Pathological Conditions, Signs and Symptoms
- Blood Loss, Surgical
- Organic Chemicals
- Pharmaceutical Preparations
- Therapeutics
- Drug Administration Routes
- Drug Therapy
- Carboxylic Acids
- Acids, Carbocyclic
- Administration, Intravenous
- Cyclohexanecarboxylic Acids
- Injections
- Tranexamic Acid
- Solutions
- Injections, Intravenous
Other Study ID Numbers
Other Study ID Numbers
- IRB-300009440
- UAB (Other Identifier: UAB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.